Molecular Tumor Board: 56-year-old male with metastatic ductal adenocarcinoma of pancreas and RET fusion

This molecular tumor board reviews tumor-agnostic biomarker testing and targeted therapy selection for RET alterations in a patient with advanced pancreatic ductal adenocarcinoma. We also provide an overview of risk factors, prognosis and biomarker-driven therapy selection underscoring the importance of comprehensive genomic profiling in patients with advanced pancreatic cancer.